Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 24, Issue 17, pp. 4066-4071
PubMed
Published By
Print ISSN
Online ISSN
History
- Received January 19, 2018
- Revision received March 23, 2018
- Accepted April 10, 2018
- Published first April 12, 2018.
Article Versions
- Previous version (April 12, 2018 - 07:54).
- Previous version (July 11, 2018 - 06:46).
- You are viewing the most recent version of this article.
Copyright & Usage
©2018 American Association for Cancer Research.
Author Information
- Gwynn Ison*,
- Lynn J. Howie,
- Laleh Amiri-Kordestani,
- Lijun Zhang,
- Shenghui Tang,
- Rajeshwari Sridhara,
- Vadryn Pierre,
- Rosane Charlab,
- Anuradha Ramamoorthy,
- Pengfei Song,
- Fang Li,
- Jingyu Yu,
- Wimolnut Manheng,
- Todd R. Palmby,
- Soma Ghosh,
- Hisani N. Horne,
- Eunice Y. Lee,
- Reena Philip,
- Kaushalkumar Dave,
- Xiao Hong Chen,
- Sharon L. Kelly,
- Kumar G. Janoria,
- Anamitro Banerjee,
- Okponanabofa Eradiri,
- Jeannette Dinin,
- Kirsten B. Goldberg,
- William F. Pierce,
- Amna Ibrahim,
- Paul G. Kluetz,
- Gideon M. Blumenthal,
- Julia A. Beaver, and
- Richard Pazdur
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
- ↵*Corresponding Author:
Gwynn Ison, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993. Phone 301-796-4057; Fax: 301-796-9849; E-mail: Gwynn.Ison{at}fda.hhs.gov
G. Ison and L.J. Howie contributed equally to this article.
September 2018
Volume 24, Issue 17
Volume 24, Issue 17
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy
Jump to section
Advertisement